Sclerostin‑related osteoporosis in type 2 diabetes mellitus, or when densitometry is not enough
Ukrainian Therapeutical Journal · 30.06.2026 · (2) · 48-53
DOI: 10.30978/utj2026-2-48 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ukrainian Therapeutical Journal, online erschienen am 30.06.2026. Verfasst von A. A. Zazdravnov und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective — to investigate serum sclerostin levels in patients with type 2 diabetes mellitus (T2DM) and to assess their relationship with changes in bone mineral density (BMD) and a history of fragility fractures. Materials and methods. 33 patients with T2DM were examined, including 14 patients with a history of fragility fractures (main group) and 19 patients without fractures (comparison group). Women predominated in both groups — 9 (64.3%) and 12 (63.2%), respectively. Osteoporosis was diagnosed using a dual‑energy X‑ray absorptiometer (DEXA). BMD was assessed at the femoral neck and lumbar spine, and results were expressed as T‑scores. Serum sclerostin levels were measured using an enzyme‑linked immunosorbent assay. Reference values for the studied parameters were obtained from a study of 20 apparently healthy individuals (control group). Statistical analysis was performed using non‑parametric methods (Pearson’s test (χ2), Cramer’s V test, Mann–Whitney U test).
Results
X‑ray densitometry of the femoral neck and lumbar spine revealed no statistically significant differences in the prevalence of osteoporosis or osteopenia between the examined groups. The T‑scores in the cohort of patients with T2DM did not differ from those in the general population of similar age and sex, and fragility fractures in these patients occurred despite unchanged BMD. Differences in serum sclerostin levels were found between patients with T2DM with a history of osteoporotic fractures and patients with T2DM without fractures, and in comparison with the control group. Significant differences were also observed in sclerostin levels between patients with type 2 diabetes without fractures and those in the control group.
Conclusions
Fragility fractures in patients with T2DM occur predominantly against a background of unchanged BMD. The known paradox of the mismatch between densitometry results and fracture risk in patients with T2DM is further complicated by the inconsistency between hypersclerostinemia and a normal T‑score. The occurrence of fragility fractures in patients with T2DM is associated with elevated serum sclerostin concentrations. Measuring sclerostin levels in patients with T2DM has high diagnostic and prognostic potential for monitoring diabetic bone disease.
Zitieren
APA
Zazdravnov, A. A., Pasiyeshvili, L. M., Taktashov, H. S., & Hrona, N. V. (2026). Sclerostin‑related osteoporosis in type 2 diabetes mellitus, or when densitometry is not enough. Ukrainian Therapeutical Journal, 48-53. https://doi.org/10.30978/utj2026-2-48
Vancouver
Zazdravnov AA, Pasiyeshvili LM, Taktashov HS, Hrona NV. Sclerostin‑related osteoporosis in type 2 diabetes mellitus, or when densitometry is not enough. Ukrainian Therapeutical Journal. 2026:48-53. doi:10.30978/utj2026-2-48
BibTeX
@article{Zazdravnov2026,
author = {Zazdravnov, A. A. and Pasiyeshvili, L. M. and Taktashov, H. S. and Hrona, N. V.},
title = {Sclerostin‑related osteoporosis in type 2 diabetes mellitus, or when densitometry is not enough},
journal = {Ukrainian Therapeutical Journal},
year = {2026},
number = {2},
pages = {48--53},
doi = {10.30978/utj2026-2-48}
}
EUVIMED